Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 681 to 690 of 1529

TitleReference numberPublishedLast updated
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancerTA707
SYNE-COV for predicting COVID-19 outcomesMIB264
Autism spectrum disorder in adults: diagnosis and managementCG142
Autism spectrum disorder in under 19s: support and managementCG170
Ozanimod for treating relapsing–remitting multiple sclerosisTA706
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancerTA705
WoundExpress to manage lower leg woundsMIB261
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal)TA702
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal)TA703
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapiesTA704

Results per page

  1. 10
  2. 25
  3. 50
  4. All